Wall Street analysts predict that Mednax, Inc (NYSE:MD) will report $867.78 million in sales for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Mednax’s earnings, with the highest sales estimate coming in at $886.40 million and the lowest estimate coming in at $853.53 million. Mednax posted sales of $828.01 million during the same quarter last year, which would indicate a positive year over year growth rate of 4.8%. The business is expected to announce its next quarterly earnings results on Thursday, October 26th.

On average, analysts expect that Mednax will report full-year sales of $867.78 million for the current fiscal year, with estimates ranging from $3.39 billion to $3.46 billion. For the next fiscal year, analysts expect that the firm will report sales of $3.64 billion per share, with estimates ranging from $3.50 billion to $3.74 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that follow Mednax.

Mednax (NYSE:MD) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm had revenue of $843.00 million for the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the prior year, the firm posted $1.03 earnings per share. Mednax’s revenue for the quarter was up 9.2% compared to the same quarter last year.

MD has been the topic of a number of research reports. BidaskClub raised shares of Mednax from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. Jefferies Group LLC reissued a “hold” rating and issued a $53.00 price target (up from $50.00) on shares of Mednax in a report on Thursday, July 6th. Mizuho restated a “neutral” rating and issued a $48.00 price target (down from $62.00) on shares of Mednax in a research report on Tuesday, August 1st. Finally, Robert W. Baird restated a “hold” rating and issued a $47.00 price target on shares of Mednax in a research report on Sunday, September 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $58.89.

In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of MD. Lord Abbett & CO. LLC bought a new position in shares of Mednax during the 2nd quarter worth approximately $14,346,000. Tandem Investment Advisors Inc. boosted its stake in Mednax by 10.5% in the 2nd quarter. Tandem Investment Advisors Inc. now owns 21,755 shares of the company’s stock valued at $1,313,000 after buying an additional 2,065 shares in the last quarter. Verition Fund Management LLC acquired a new stake in Mednax in the 2nd quarter valued at $516,000. Grandeur Peak Global Advisors LLC boosted its stake in Mednax by 6.5% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 200,125 shares of the company’s stock valued at $12,082,000 after buying an additional 12,300 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its stake in Mednax by 2.4% in the 2nd quarter. Sterling Capital Management LLC now owns 1,048,652 shares of the company’s stock valued at $63,307,000 after buying an additional 24,228 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/mednax-inc-md-expected-to-post-quarterly-sales-of-867-78-million.html.

Mednax (NYSE:MD) opened at 44.80 on Wednesday. The company has a market cap of $4.13 billion, a P/E ratio of 14.27 and a beta of 0.37. The firm’s 50-day moving average price is $43.02 and its 200-day moving average price is $54.41. Mednax has a 12-month low of $40.78 and a 12-month high of $72.13.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on Mednax (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.